B-cell memory and primary immune deficiencies: Interleukin-21 related defects

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 6, 2013, Pages 639-645

  Desjardins, Marylin ^a,b   Mazer, Bruce D ^a,b  

^a Clinical Immunology Allergy and Asthma   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

B cell memory; Common variable immune deficiency; Humoral immune response; Interleukin 21; Primary immune deficiency

Indexed keywords

B CELL MATURATION ANTIGEN; CD38 ANTIGEN; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; JANUS KINASE 3; STAT3 PROTEIN;

CELL DIFFERENTIATION; CELL MATURATION; COMMON VARIABLE IMMUNODEFICIENCY; HUMAN; HYPER IGE SYNDROME; IMMUNE DEFICIENCY; IN VITRO STUDY; IPEX SYNDROME; JAK3 DEFICIENCY; LOSS OF FUNCTION MUTATION; MEMORY CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VACCINATION; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; ANTIGENS, CD38; B-LYMPHOCYTES; CYTIDINE DEAMINASE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC MEMORY; INTERLEUKIN-21 RECEPTOR ALPHA SUBUNIT; INTERLEUKINS; JANUS KINASE 3; JOB SYNDROME; KILLER CELLS, NATURAL; MEMBRANE GLYCOPROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TH17 CELLS;

EID: 84889886947     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000009     Document Type: Review

References (52)

1. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:34-48.
2. Pieper K, Grimbacher B, Eibel H. B-cell biology and development. J Allergy Clin Immunol 2013; 131:959-971. A review discussing critical stages in B-cell development on the basis of characterized genetic defects associated with primary immune deficiencies.
3. Yong PF, Tarzi M, Chua I, et al. Common variable immunodeficiency: An update on etiology and management. Immunol Allergy Clin North Am 2008; 28:367-386.
4. Vale AM, Schroeder HW. Clinical consequences of defects in B-cell development. J Allergy Clin Immunol 2010; 125:778-787.
5. Warnatz K, Schlesier M. Flowcytometric phenotyping of common variable immunodeficiency. Clin Cytometry 2008; 74B:261-271.
6. Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008; 111:77-85.
7. Ozaki K, Spolski R, Feng CG, et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002; 298:1630-1634.
8. Recher M, Berglund LJ, Avery DT, et al. IL-21 is the primary common y chainbinding cytokine required for human B-cell differentiation in vivo. Blood 2011; 118:6824-6835. A description of the abnormal signalling through a mutated common gamma-chain of the IL-21 receptor and its association with persistent humoral abnormalities found after bone marrow transplantation of X-linked and JAK3 SCID patients with incomplete chimerism.
9. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte fonction. Nature 2000; 408:57-63.
10. Ozaki K, Kikly K, Michalovich D, et al. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci U S A 2000; 97:11439-11444.
11. Kotlarz D, Zietara N, Uzel G, et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med 2013; 210:433-443. First study of homozygotous loss-of-function mutations of the IL-21 receptor gene found in two unrelated kindreds affected by cryptosporidial- related cholangitis evolving to severe liver disease.
12. Metha DS, Wurster AL, Grusby MJ. Biology of IL-21 and the IL-21 receptor. Immunol Rev 2004; 202:84-95.
13. Asao H, Okuyama C, Kumaki S, et al. Cutting edge: the common gammachain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001; 167:1-5.
14. Avery DT, Deenick EK, Ma CS, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 2010; 207:155-171. A description of the critical and nonredundant role of STAT3 in B-cell production of high-affinity specific antibodies and differentiation into immunoglobulin-secreting cells.
15. Jin H, Carrrio R, Yu A, Malek TR. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 2004; 173:657-665.
16. Hagn M, Jahrsdo rfer B. Why do human B cells secrete granzyme B? Oncoimmunology 2012; 1:1368-1375. A review discussing the autocrine and paracrine functions of IL-21 as a regulatory cytokine and a cytokine that promotes B-cell differentiation into immunoglobulinsecreting cells depending on the specific costimulation applied.
17. Hagn M, Schwesinger E, Ebel V, et al. Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J Immunol 2009; 183:1838-1845.
18. Hagn M, Sontheimer K, Dahlke K, et al. Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help. Immunol Cell Biol 2012; 90:457-467.
19. Clemente A, Pons J, Matamoros N, et al. B cells from common variable immunodeficiency patients fail to differentiate to antibody secreting cells in response to TLR9 ligand (CpG-ODN) or anti-CD40 ; IL21. Cell Immunol 2011; 268:9-15. A description of decreased B-cell differentiation into immunoglobulin-secreting cells and antibody production following IL-21 in-vitro stimulation in patients with CVID.
20. Ettinger E, Sims GP, Fairhurst A, et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005; 175:7867-7879.
21. Tangye SG, Avery DT, Deenick EK, Hodgkin PD. Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J Immunol 2003; 170:686-694.
22. Bryant VL, Ma CS, Avery DT, et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5 ; T follicular helper cells. J Immunol 2007; 179:8180-8190.
23. Karnell JL, Ettinger R. The interplay of IL-21 and BAFF in the formation and maintenance of human B cell memory. Front Immunol 2012; 3:1-9. A review discussing complementary and sometimes synergistic effects of BAFF and IL-21 on B-cell growth and differentiation.
24. Holland SM, DeLeo FR, Elloumi HD, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007; 357:1608-1619.
25. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in DNAbinding domain of STAT3 cause hyper-IgE syndrome. Nature 2007; 448:1058-1062.
26. Renner ED, Rylaarsdam S, Anover-Sombke S, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced TH17 cells numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol 2008; 122:181-187.
27. Leung DY, Ambrosino DM, Arbeit RD, et al. Impaired antibody responses in the hyperimmunoglobulin E syndrome. J Allergy Clin Immunol 1988; 81: 1082-1087.
28. Litinskiy MB, Nardelli DM, Hilbert B, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3:822-829.
29. Xu W, Santini PA, Matthews AJ, et al. Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. J Immunol 2008; 181:276-287.
30. Erazo A, Kutchukhidze N, Leung M, et al. Unique maturation program of the IgE response in vivo. Immunity 2007; 26:191-203.
31. Liu X, Nickel R, Beyer K, et al. An IL13 coding region variant is associated with a high total serum IgE level and atopic dermatitis in the German Multicenter Atopy Study (MAS-90). J Allergy Clin Immunol 2000; 106:167-170.
32. Wesemann DR, Magee JM, Boboila C, et al. Immature B cells preferentially switch to IgE with increased direct Smu to Sepsilon recombination. JEM 2011; 208:2733-2746.
33. Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or posttransplant GVHD prophylaxis. J Pediatr 2009; 155:834-840.
34. Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res 2011; 49: 25-43.
35. Wolska-Kusnierz B, Bajer A, Caccio S, et al. Cryptosporidium infection in patients with primary immunodeficiencies. J Pediatr Gastroenterol Nutr 2007; 45:458-464.
36. Nurieva R, Yang RO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448:480-483.
37. Ahn S, Cunningham-Rundles C. Role of B cells in common variable immune deficiency. Expert Rev Clin Immunol 2009; 5:557-564.
38. Park M, Li J, Hagan J, et al. Common variable immunodeficiency: A new look at an old disease. Lancet 2008; 372:489-502.
39. Glocker E, Ehl S, Grimbacher B. Common variable immunodeficiency in children. Curr Opin Pediatr 2007; 19:685-692.
40. Castigli E, Geha RS. Molecular basis of common variable immunodeficiency. J Allergy Clin Immunol 2006; 117:740-746.
41. Warnatz K, Denz A, Drager R, et al. Severe deficiency of switched memory B cells (CD27( ;)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: A new approach to classify a heterogeneous disease. Blood 2002; 99:1544-1551.
42. Piqueras B, Lavenu-Bombled C, Galicier L, et al. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. J Clin Immunol 2003; 23:385-400.
43. Salzer U, Neumann C, Thiel J, et al. Screening of functional and positional candidate genes in families with common variable immunodeficiency. BMC Immunol 2008; 9:3.
44. Desjardins M,MazerBD.Impaired in vitro capacity to undergo IgGisotype classswitching (ICS) in response to interleukin-21 (IL21) stimulation in common variable immunodeficiency (CVID). J Allergy Clin Immunol 2013; 131:AB70.
45. Borte S, Pan-Hammarstrom Q, Liu C, et al. Interleukin-21 restores immunoglobulin production ex vivo in patients with common variable immunodeficiency and selective IgA deficiency. Blood 2009; 114:4089-4098.
46. Attridge K, Wang CJ, Wardzinski L, et al. IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood 2012; 119:4656-4664. A description of the overlapping role between IL-2 and IL-21 in supporting conventional T-cell expansion, but their distinct capacity to support regulatory T cells homeostasis.
47. Terrier B, Costedoat-Chalumeau N, Garrido M, et al. Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol 2012; 39:1819-1828.
48. Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol 2011; 128:655-664.
49. Jia HY, Zhang ZG, Gu XJ, et al. Association between interleukin 21 and Graves' disease. Genet Mol Res 2011; 10:3338-3346.
50. Maurer MF, Garrigues U, Jaspers SR, et al. Generation and characterization of human antihuman IL-21 neutralizing monoclonal antibodies. MABs 2012; 4:69-83.
51. Steele N, Anthony A, Saunders M, et al. A phase I trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. Br J Cancer 2012; 106:793-798.
52. Timmerman JM, Byrd JC, Andorsky DJ, et al. A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res 2012; 18: 5752-5760.